“Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-Oesophageal Junction Adenocarcinoma”. Molecular Medicine Communications 3, no. 02 (December 29, 2023): 89–92. Accessed April 3, 2026. https://rootspress.org/journals/MMC/article/view/461.